GlassScriptPhysician profile
Dante S Raneses
NPI 1710978820
$9,944.17
in general payments reported to CMS, 2019-2025
39 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,964 · 2020: $1,361 · 2021: $1,675 · 2022: $1,137 · 2023: $1,355 · 2024: $736 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,557.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $897.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $876.39 | 2019-2022 | |
| Abbvie INC. | $758.94 | 2021-2025 | |
| Pfizer INC. | $701.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $490.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $475.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.67 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $326.69 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $311.93 | 2019-2022 | |
| Exact Sciences Corporation | $294.34 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $273.06 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $268.39 | 2021-2024 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $261.96 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $216.88 | 2021-2024 | Gvoke Hypopen |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dante Raneses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.